We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica
News

Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica

Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica
News

Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced a new two-year target discovery collaboration between Janssen Pharmaceutica and BioFocus DPI, Galapagos’ service division, in the field of oncology.

BioFocus DPI will apply Galapagos’ proprietary adenoviral platform to identify drug targets for the development of cancer therapies.

The goal of the new collaboration will be to discover and validate novel targets in the field of oncology. BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation. Target discovery in in-vitro assays may provide drug targets for cancer areas with an unmet medical need.

BioFocus DPI receives an upfront payment of €2.9 million. In total, BioFocus DPI may receive additional research, acceptance, license and development fees of up to €7.6 million should certain predetermined criteria be achieved.

“This marks BioFocus DPI’s first target discovery agreement in oncology, as well as the largest target discovery agreement to date for the service division,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.

Advertisement